Brief: Matinas Biopharma Holdings Reports Q3 Loss Per Share Of $0.03

Matinas BioPharma Holdings

13/11/2019 12:17

Nov 13 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA REPORTS THIRD QUARTER 2019 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
    * Q3 LOSS PER SHARE $0.03
    * Q3 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES
DATA
    * CASH AND CASH EQUIVALENTS AT SEPTEMBER 30, 2019 WERE
APPROXIMATELY $32.7 MILLION
    * INITIATED PRE-SCREENING OF PATIENTS FOR PHASE 2 ENHANCE-IT
STUDY
OF MAT9001 AGAINST VASCEPA
    * BELIEVES THAT CASH ON HAND IS SUFFICIENT TO FUND
OPERATIONS INTO
Q1 OF 2021
    * PHASE 2 ENHANCE-IT STUDY OF MAT9001 ENROLLMENT TO COMMENCE
Q1
2020, WITH TOPLINE DATA EXPECTED H2 2020

Source text for Eikon:  ID:nGNXbKs3mH 
Further company coverage:  MTNB.A 

 (Reuters.Briefs@thomsonreuters.com)